OP13: Postoperative Crohn’s disease recurrence: unanswered questions and future directions in diagnosis, pathophysiology, prevention and treatment. Conclusions from the 8th ECCO Scientific workshop.ECCO’23 Copenhagen 2023
OP14: Prevention of postoperative recurrence of Crohn's disease with vedolizumab: First results of the prospective placebo-controlled randomised trial REPREVIOECCO’23 Copenhagen 2023
OP15: Efficacy of ustekinumab for Ulcerative Colitis through 4 years: Final clinical and endoscopy outcomes from the UNIFI long-term extensionECCO’23 Copenhagen 2023
OP16: Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologicsECCO’23 Copenhagen 2023
OP17: Upadacitinib Improves Endoscopic Outcomes in Patients with Moderate to Severely Active Crohn’s Disease Irrespective of Previous Failure to Respond to Biologics or Conventional TherapiesECCO’23 Copenhagen 2023
OP18: Disease course of Crohn’s disease during the first ten years following diagnosis in a prospective European population-based inception cohort – the Epi-IBD cohortECCO’23 Copenhagen 2023
OP19: Gaps between ECCO quality standards of care and the real world: the E-QUALITY surveyECCO’23 Copenhagen 2023
OP21: COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide DataECCO’23 Copenhagen 2023
OP22: The risk of cancer in pediatric-onset immune-mediated inflammatory diseases – a nationwide Danish study from 1980-2018.ECCO’23 Copenhagen 2023
OP23: Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in CataloniaECCO’23 Copenhagen 2023
OP25: Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative dataECCO’23 Copenhagen 2023
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trialECCO’23 Copenhagen 2023
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCUECCO’23 Copenhagen 2023
OP28: Children and young adults with inflammatory bowel disease have an increased incidence and risk of developing mental health conditions: a UK population-based cohort studyECCO’23 Copenhagen 2023
OP29: Peri-natal exposure to parental Crohn’s disease is associated with impaired gut barrier, microbiome composition differences and increased risk of Crohn’s diseaseECCO’23 Copenhagen 2023
OP32: The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivoECCO’23 Copenhagen 2023